- Home
- Publications
- Publication Search
- Publication Details
Title
Rare molecular subtypes of lung cancer
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 20, Issue 4, Pages 229-249
Publisher
Springer Science and Business Media LLC
Online
2023-02-20
DOI
10.1038/s41571-023-00733-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors
- (2022) George D. Demetri et al. CLINICAL CANCER RESEARCH
- Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial
- (2022) Julien Mazieres et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypersensitivity Reactions to Selpercatinib Treatment with or Without Prior Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer in LIBRETTO-001
- (2022) Caroline E. McCoach et al. Journal of Thoracic Oncology
- KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
- (2022) Zhongwei Mao et al. Cell Discovery
- Transcriptomic profiling of single circulating tumor cells provides insight into human metastatic gastric cancer
- (2022) Ryo Negishi et al. Communications Biology
- Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma
- (2022) Virginia Aragon-Sanabria et al. CLINICAL CANCER RESEARCH
- ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
- (2022) Wenjing Su et al. MOLECULAR CELL
- Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
- (2022) James C. H. Yang et al. BMC CANCER
- Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
- (2022) Yasir Y. Elamin et al. CANCER CELL
- Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).
- (2022) Helena Alexandra Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).
- (2022) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
- (2022) Catherine A. Shu et al. JOURNAL OF CLINICAL ONCOLOGY
- CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.
- (2022) Daniel R. Carrizosa et al. JOURNAL OF CLINICAL ONCOLOGY
- Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.
- (2022) Matthew Krebs et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
- (2022) Alison M. Schram et al. JOURNAL OF CLINICAL ONCOLOGY
- Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
- (2022) Daniel Zingg et al. NATURE
- Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
- (2022) Rupert Bartsch et al. NATURE MEDICINE
- Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC
- (2022) Francesco Passiglia et al. CANCER TREATMENT REVIEWS
- Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors
- (2022) James P. Solomon et al. CLINICAL CANCER RESEARCH
- Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)
- (2022) Florian Guisier et al. Clinical Lung Cancer
- EP08.02-148 Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
- (2022) V. Moreno et al. Journal of Thoracic Oncology
- PROTAC therapy as a new targeted therapy for lung cancer
- (2022) Jennifer W. Li et al. MOLECULAR THERAPY
- Protein kinase C fusion proteins are paradoxically loss-of-function in cancer
- (2021) An-Angela N. Van et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Crizotinib in Patients With MET-Amplified NSCLC
- (2021) D. Ross Camidge et al. Journal of Thoracic Oncology
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Mutant-selective degradation by BRAF-targeting PROTACs
- (2021) Shanique Alabi et al. Nature Communications
- Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
- (2021) Zhenfang Du et al. Nature Communications
- Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA
- (2021) Thomas L. Dunwell et al. Scientific Reports
- Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway
- (2021) Jian Carrot-Zhang et al. Cell Reports
- Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
- (2021) Jason C. Chang et al. CLINICAL CANCER RESEARCH
- Clinical Experience of Cerebrospinal Fluid–Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling
- (2021) Tejus A. Bale et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
- (2021) J. Rotow et al. Journal of Thoracic Oncology
- Revealing the BRD4-NOTCH3 fusion: A novel hill in the cancer landscape
- (2021) Fabiano de Almeida Costa et al. LUNG CANCER
- Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers
- (2021) Nobuhiko Hasegawa et al. CANCER SCIENCE
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- (2021) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
- (2021) Yasir Y. Elamin et al. JOURNAL OF CLINICAL ONCOLOGY
- Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).
- (2021) Xiuning Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
- (2021) Alexander Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
- (2021) Justin F Gainor et al. LANCET ONCOLOGY
- TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
- (2021) Brion W. Murray et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
- (2021) Bob T. Li et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
- (2021) A. Rose Brannon et al. Nature Communications
- Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
- (2021) Pasi A. Janne et al. Cancer Discovery
- Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
- (2021) Leora Horn et al. JAMA Oncology
- Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
- (2021) Marcelo V Negrao et al. Journal for ImmunoTherapy of Cancer
- Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA
- (2021) Justin D. Finkle et al. npj Precision Oncology
- Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
- (2021) Zhengbo Song et al. CLINICAL CANCER RESEARCH
- The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
- (2021) Hiroki Izumi et al. NATURE
- EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
- (2021) Alex Friedlaender et al. Nature Reviews Clinical Oncology
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
- (2021) Robert Roskoski Jr. PHARMACOLOGICAL RESEARCH
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
- (2021) Caicun Zhou et al. JAMA Oncology
- Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
- (2020) Danielle Cohen et al. Journal of Thoracic Oncology
- Genomic landscape of lung adenocarcinoma in East Asians
- (2020) Jianbin Chen et al. NATURE GENETICS
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
- (2020) Alexander Drilon et al. NATURE MEDICINE
- TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study
- (2020) T. Mok et al. ANNALS OF ONCOLOGY
- Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer
- (2020) Alissa J. Cooper et al. CLINICAL CANCER RESEARCH
- Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
- (2020) Mi Ran Yun et al. CLINICAL CANCER RESEARCH
- Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+).
- (2020) Shun Lu et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in Non-Small Cell Lung Cancer
- (2020) Hanny Al-Samkari et al. Journal of Thoracic Oncology
- A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer
- (2020) Marliese Alexander et al. LUNG CANCER
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
- (2020) Shaokun Liu et al. Frontiers in Oncology
- Rare cancers are not rare in Asia as well: The rare cancer burden in East Asia
- (2020) Tomohiro Matsuda et al. Cancer Epidemiology
- Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
- (2020) Caicun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- The National Lung Matrix Trial of personalized therapy in lung cancer
- (2020) Gary Middleton et al. NATURE
- MET-dependent solid tumours — molecular diagnosis and targeted therapy
- (2020) Robin Guo et al. Nature Reviews Clinical Oncology
- ROS1-dependent cancers — biology, diagnostics and therapeutics
- (2020) Alexander Drilon et al. Nature Reviews Clinical Oncology
- An ErbB2 splice variant lacking exon 16 drives lung carcinoma
- (2020) Harvey W. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Precision medicine in non-small cell lung cancer: Current applications and future directions
- (2020) Soo-Ryum Yang et al. SEMINARS IN CANCER BIOLOGY
- Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers
- (2020) Hoon Kim et al. NATURE GENETICS
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin
- (2020) Ryan Woodhouse et al. PLoS One
- TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
- (2020) Emiliano Cocco et al. Cancer Discovery
- The efficacy of ado-trastuzumab emtansine in patients with ERBB2-aberrant non-small cell lung cancer: a systematic review
- (2020) Xiu Huang et al. Translational Cancer Research
- A Performance Comparison of Commonly Used Assays to Detect RET Fusions
- (2020) Soo-Ryum Yang et al. CLINICAL CANCER RESEARCH
- Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer
- (2020) Elie Dolgin NATURE
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- RIT1 oncoproteins escape LZTR1-mediated proteolysis
- (2019) Pau Castel et al. SCIENCE
- Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib
- (2019) A J Schoenfeld et al. ANNALS OF ONCOLOGY
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
- (2019) A T Shaw et al. ANNALS OF ONCOLOGY
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
- (2019) Natasha B. Leighl et al. CLINICAL CANCER RESEARCH
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
- (2019) Kurtis D. Davies et al. Journal of Thoracic Oncology
- Gene of the Month: Neuregulin-1 fusion positive NSCLC (NRG1+ NSCLC)
- (2019) Misako Nagasaka et al. Journal of Thoracic Oncology
- CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition
- (2019) Amir Noeparast et al. ONCOGENE
- A Phase 2 Study of Lenvatinib in Patients With RET Fusion-Positive Lung Adenocarcinoma
- (2019) Toyoaki Hida et al. LUNG CANCER
- Targeted deep sequencing of cell‐free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology
- (2019) Soo‐Ryum Yang et al. CANCER CYTOPATHOLOGY
- Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer
- (2019) Yijia Guo et al. OncoTargets and Therapy
- Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU
- (2019) Kerstin Noëlle Vokinger et al. BMJ Open
- TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
- (2019) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
- (2019) Alice T Shaw et al. LANCET ONCOLOGY
- Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
- (2019) Erik Tambuyzer et al. NATURE REVIEWS DRUG DISCOVERY
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
- (2018) Yan Wang et al. BMC CANCER
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- (2018) Francisco Sanchez-Vega et al. CELL
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- (2018) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples
- (2018) Kurtis D. Davies et al. Journal of Thoracic Oncology
- The incidence of brain metastases in stage IV ROS1 -rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib
- (2018) Tejas Patil et al. Journal of Thoracic Oncology
- FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer
- (2018) Kaixuan Wang et al. ONCOGENE
- Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
- (2018) Alexander Drilon et al. Cancer Discovery
- Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer
- (2018) Jessica J. Lin et al. Journal of Thoracic Oncology
- Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling
- (2018) Angel Qin et al. Journal of Thoracic Oncology
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1491PA phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial
- (2018) I Kinoshita et al. ANNALS OF ONCOLOGY
- Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins
- (2018) Dana S. Neel et al. CANCER RESEARCH
- Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
- (2018) Brian P Hobbs et al. JNCI-Journal of the National Cancer Institute
- RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
- (2018) Zhan Yao et al. NATURE MEDICINE
- ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events
- (2018) Terry L. Ng et al. Journal of Thoracic Oncology
- BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies.
- (2017) Venkataprasanth P. Reddy et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- (2017) Oliver Gautschi et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
- (2017) Sun Min Lim et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels
- (2017) Brigitte Poirot et al. Journal of Thoracic Oncology
- Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
- (2017) Alexander Drilon et al. Journal of Thoracic Oncology
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
- (2017) Zhan Yao et al. NATURE
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
- (2016) S.-H. Lee et al. ANNALS OF ONCOLOGY
- Clinical outcomes with pemetrexed-based systemic therapies inRET-rearranged lung cancers
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
- (2016) J. H. Tong et al. CLINICAL CANCER RESEARCH
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations
- (2016) Yen-Fu Chen et al. Journal of Thoracic Oncology
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Adaptive Designs for Clinical Trials
- (2016) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib
- (2015) Jarushka Naidoo et al. CANCER
- Lung Master Protocol (Lung-MAP)--A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
- (2015) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a -Secretase Inhibitor
- (2015) K. Wang et al. CLINICAL CANCER RESEARCH
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung
- (2015) Hyo Sup Shim et al. Journal of Thoracic Oncology
- Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS)
- (2015) Hussam Al-Kateb et al. Molecular Oncology
- Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
- (2015) Matthew T Chang et al. NATURE BIOTECHNOLOGY
- HER2missense mutations have distinct effects on oncogenic signaling and migration
- (2015) Daniel J. Zabransky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors
- (2015) Daniel H. Hovelson et al. NEOPLASIA
- RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
- (2014) K Tsuta et al. BRITISH JOURNAL OF CANCER
- MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
- (2014) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- The Minority Report: Targeting the Rare Oncogenes in NSCLC
- (2014) Caroline E. McCoach et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
- (2014) Seung Eun Lee et al. MODERN PATHOLOGY
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic RIT1 mutations in lung adenocarcinoma
- (2014) A H Berger et al. ONCOGENE
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. Journal of Thoracic Oncology
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
- (2012) P. Perez-Moreno et al. CLINICAL CANCER RESEARCH
- Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas
- (2012) Michiya Nishino et al. MODERN PATHOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
- (2011) Arvin C. Dar et al. Annual Review of Biochemistry
- Rare cancers are not so rare: The rare cancer burden in Europe
- (2011) Gemma Gatta et al. EUROPEAN JOURNAL OF CANCER
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- (2011) Antonio Marchetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
- (2011) D. Ross Camidge et al. Journal of Thoracic Oncology
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
- (2008) G. J. Riely et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started